Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion

BACKGROUND: Renal cell carcinomas (RCC) harboring a TFE3 gene fusion (TfRCC) represent an aggressive subset of kidney tumors. Key signaling pathways of TfRCC are unknown and preclinical in vivo data are lacking. We investigated Akt/mTOR pathway activation and the preclinical efficacy of dual mTORC1/...

Descripción completa

Detalles Bibliográficos
Autores principales: Kauffman, Eric C., Lang, Martin, Rais-Bahrami, Soroush, Gupta, Gopal N., Wei, Darmood, Yang, Youfeng, Sourbier, Carole, Srinivasan, Ramaprasad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743205/
https://www.ncbi.nlm.nih.gov/pubmed/31519159
http://dx.doi.org/10.1186/s12885-019-6096-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743205/
https://www.ncbi.nlm.nih.gov/pubmed/31519159
http://dx.doi.org/10.1186/s12885-019-6096-0

Ejemplares similares